B vitamin therapy for homocysteine: Renal function and vitamin B12 determine cardiovascular outcomes

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 3, 2013, Pages 633-637

  Spence, John David ^a  

^a NONE

Author keywords

B vitamins; Homocysteine; Stroke

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; PYRIDOXINE;

ABSORPTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONFERENCE PAPER; CYANOCOBALAMIN DEFICIENCY; DRUG DOSE COMPARISON; DRUG MEGADOSE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; PRIORITY JOURNAL; RISK REDUCTION; THROMBOCYTE AGGREGATION; TREATMENT RESPONSE; VITAMIN BLOOD LEVEL;

AGED; CLINICAL TRIALS AS TOPIC; GLOMERULAR FILTRATION RATE; HUMANS; RENAL INSUFFICIENCY; RISK FACTORS; STROKE; VITAMIN B 12; VITAMIN B 12 DEFICIENCY;

EID: 84882338504     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0465     Document Type: Conference Paper

References (44)

1. Spence JD, Stampfer MJ. Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses. J Am Med Assoc 2011;306:2610-1.
2. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
3. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
4. Robertson J, Iemolo F, Stabler SP, Allen RH, Spence JD. Vitamin B12, homocysteine and carotid plaque in the era of folic acid fortification of enriched cereal grain products. CMAJ 2005;172:1569-73.
5. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-6.
6. Graham IM, Daly L, Refsum H, Robinson K, Brattstrom LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. J Am Med Assoc 1997;277:1775-81.
7. Zhou J, Moller J, Ritskes-Hoitinga M, Larsen ML, Austin RC, Falk E. Effects of vitamin supplementation and hyperhomocysteinemia on atherosclerosis in apoE-deficient mice. Atherosclerosis 2003;168:255-62.
8. Colgan SM, Austin RC. Homocysteinylation of metallothionein impairs intracellular redox homeostasis: the enemy within! Arterioscler Thromb Vasc Biol 2007;27:8-11.
9. Veeranna V, Zalawadiya SK, Niraj A, Pradhan J, Ference B, Burack RC, et al. Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol 2011;58:1025-33.
10. Holmes MV, Newcombe P, Hubacek JA, Sofat R, Ricketts SL, Cooper J, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. Lancet 2011;378:584-94.
11. Rimm EB, Stampfer MJ. Folate and cardiovascular disease: one size does not fit all. Lancet 2011;378:544-6.
12. Herrmann W, Obeid R, Schorr H, Geisel J. The usefulness of holotranscobalamin in predicting vitamin B12 status in different clinical settings. Curr Drug Metab 2005;6:47-53.
13. Andres E, Loukili NH, Noel E, Kaltenbach G, Abdelgheni MB, Perrin AE, et al. Vitamin B12 (cobalamin) deficiency in elderly patients. CMAJ 2004;171:251-9.
14. Spence JD. Nutrition and stroke prevention. Stroke 2006;37:2430-5.
15. Vogiatzoglou A, Oulhaj A, Smith AD, Nurk E, Drevon CA, Ueland PM, et al. Determinants of plasma methylmalonic acid in a large population: implications for assessment of vitamin B12 status. Clin Chem 2009;55:2198-206.
16. Bang H, Mazumdar M, Spence JD. Tutorial in biostatistics: analyzing associations between total plasma homocysteine and B vitamins using optimal categorization and segmented regression. Neuroepidemiology 2006;27:188-200.
17. Rajan S, Wallace JI, Brodkin KI, Beresford SA, Allen RH, Stabler SP. Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults. J Am Geriatr Soc 2002;50:1789-95.
18. Refsum H, Smith AD. Homocysteine, B vitamins, and cardiovascular disease. N Engl J Med 2006;355:207.
19. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 2007;6:830-8.
20. Poli D, Antonucci E, Cecchi E, Marcucci R, Liotta AA, Cellai AP, et al. Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke 2005;36:2159-63.
21. Spence JD, Tamayo A, Lownie SP, Ng WP, Ferguson GG. Absence of microemboli on transcranial Doppler identifies low-risk patients with asymptomatic carotid stenosis. Stroke 2005;36:2373-8.
22. Madani A, Beletsky V, Tamayo A, Munoz C, Spence JD. High-risk asymptomatic carotid stenosis: ulceration on 3D ultrasound versus TCD microemboli. Neurology 2011;77:744-50.
23. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005;111:2233-40.
24. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
25. Spence JD. Mechanisms of thrombogenesis in atrial fibrillation. Lancet 2009;373:1006.
26. Clarke R, Halsey J, Lewington S, Lonn E, Armitage J, Manson JE, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010;170:1622-31.
27. Huang T, Chen Y, Yang B, Yang J, Wahlqvist ML, Li D. Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality. Clin Nutr 2012;31:448-54.
28. Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. Br Med J 2010;341:c6273.
29. Alsagaff MY, Thaha M, Aminuddin M, Yogiarto RM, Yogiantoro M, Tomino Y. Asymmetric dimethylarginine: a novel cardiovascular risk factor in end-stage renal disease. J Int Med Res 2012;40:340-9.
30. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, et al. Endothelial dysfunction induced by hyperhomocyst (e) inemia: role of asymmetric dimethylarginine. Circulation 2003;108:933-8.
31. Wilcox CS. Asymmetric dimethylarginine and reactive oxygen species: unwelcome twin visitors to the cardiovascular and kidney disease tables. Hypertension 2012;59:375-81.
32. Van GC, Nanayakkara PW, Stehouwer CD. Homocysteine and asymmetric dimethylarginine (ADMA): biochemically linked but differently related to vascular disease in chronic kidney disease. Clin Chem Lab Med 2007;45:1683-7.
33. Rocha MS, Teerlink T, Janssen MC, Kluijtmans LA, Smulders Y, Jakobs C, et al. Asymmetric dimethylarginine in adults with cystathionine beta-synthase deficiency. Atherosclerosis 2012;222:509-11.
34. Rueda-Clausen CF, Cordoba-Porras A, Bedoya G, Silva FA, Zarruk JG, Lopez-Jaramillo P, et al. Increased plasma levels of total homocysteine but not asymmetric dimethylarginine in Hispanic subjects with ischemic stroke FREC-VI sub-study. Eur J Neurol 2012;19:417-25.
35. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering plasma total homocysteine to prevent recurrent stroke, myocardial infarction, and death in ischemic stroke patients: results of the Vitamin Intervention for Stroke Prevention (VISP) Randomized Trial. J Am Med Assoc 2004;291:565-75.
36. Spence JD, Cordy P, Kortas C, Freeman D. Effect of usual doses of folate supplementation on elevated plasma homocyst (e) ine in hemodialysis patients: no difference between 1 and 5 mg daily. Am J Nephrol 1999;18:405-10.
37. House AA, Eliasziw M, Cattran DC, Churchill DN, Oliver MJ, Fine A, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. J Am Med Assoc 2010;303:1603-9.
38. Loscalzo J. Homocysteine trials - clear outcomes for complex reasons. N Engl J Med 2006;354:1629-32.
39. Obeid R, Shannan B, Herrmann W. Advanced glycation end products overload might explain intracellular cobalamin deficiency in renal dysfunction, diabetes and aging. Med Hypotheses 2011;77:884-8.
40. Koyama K, Yoshida A, Takeda A, Morozumi K, Fujinami T, Tanaka N. Abnormal cyanide metabolism in uraemic patients. Nephrol Dial Transplant 1997;12:1622-8.
41. Wang R. Is H2S a stinky remedy for atherosclerosis? Arterioscler Thromb Vasc Biol 2009;29:156-7.
42. Koyama K, Ito A, Yamamoto J, Nishio T, Kajikuri J, Dohi Y, et al. Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis. Am J Kidney Dis 2010;55:1069-78.
43. Hasuike Y, Nakanishi T, Moriguchi R, Otaki Y, Nanami M, Hama Y, et al. Accumulation of cyanide and thiocyanate in haemodialysis patients. Nephrol Dial Transplant 2004;19:1474-9.
44. Perna AF, Luciano MG, Ingrosso S, Pulzella P, Sepe I, Lanza D, et al. Hydrogen sulphide-generating pathways in haemodialysis patients: a study on relevant metabolites and transcriptional regulation of genes encoding for key enzymes. Nephrol Dial Transplant 2009;24:3756-63.